Novo Nordisk recently announced positive results from its Phase 3b Dual VII clinical trial for Xultophy, a product created to treat Type 2 diabetes.
Results from the study showed that Xultophy, when compared to treatment with basal-bolus therapy, demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with Type 2 diabetes.
Novo Nordisk showcased the results of the study at the American Diabetes Association’s 77th Scientific Sessions in San Diego, California.
"The results of Dual VII show that Xultophy 100/3.6 provided a similar reduction in A1C compared to basal-bolus therapy while significantly reducing the number of hypoglycemic events along with a reduction in weight," Dr. Todd Hobbs, U.S. chief medical officer for Novo Nordisk, said in a statement. "These findings reinforce the importance of the ongoing development of new medicines to help adults better manage their Type 2 diabetes."
Novo Nordisk is a global health care company that brings 90 years of innovation and leadership to the fight against diabetes. Its U.S. headquarters are in Plainsboro, N.J.
Alerts Sign-up